Henggliflozin Combined with Probiotics

Preclinical

TThe First Affiliated Hospital of Air Force Medicial University

Henggliflozin Combined with Probiotics is one of 2 therapeutic programs targeting Heart Failure Preserved Ejection Fraction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Heart Failure Preserved Ejection FractionNot yet recruiting

Heart Failure Preserved Ejection FractionPreclinical

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Heart Failure Preserved Ejection Fraction

#DrugCompanyPhaseTrials

Henggliflozin

XXinhua Hospital, Shanghai Jiao Tong University School of Medicine

Preclinical

1 2

Henggliflozin Combined with Probiotics

TThe First Affiliated Hospital of Air Force Medicial University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalNot yet recruiting

Heart Failure Preserved Ejection Fraction

NCT07687212

Clinical

Trials by Indication[1]

Heart Failure Preserved Ejection Fraction1 trial

Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF

Not yet recruiting·TThe First Affiliated Hospital of Air Force Medicial University·Preclinical·NCT07687212·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Henggliflozin Combined with Probiotics. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Henggliflozin Combined with Probiotics. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — The First Affiliated Hospital of Air Force Medicial University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: TThe First Affiliated Hospital of Air Force Medicial University

Henggliflozin Combined with Probiotics

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Heart Failure Preserved Ejection Fraction1 trial

References

Drug Info

Quick Facts

Related News